Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.39 |
| ▸ | NOS2 | P35228 | 6/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12134876 | 0.83 | PTGDR2 (0.34) | CYP2D6PTGDR2CYP1A2DHODH | |
| SCHEMBL12092017 | 0.80 | CYP1A2 (0.33) | SMN1; SMN2ALDH1A1KDM4EHTR2BPTGDR2 | |
| SCHEMBL12092014 | 0.80 | CYP1A2 (0.33) | SMN1; SMN2ALDH1A1KDM4EHTR2BPTGDR2 | |
| SCHEMBL12092011 | 0.80 | CYP1A2 (0.33) | SMN1; SMN2ALDH1A1KDM4EHTR2BPTGDR2 | |
| SCHEMBL14047000 | 0.73 | TSHR (0.36) | CYP2D6SLC6A4NOS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL14092173 | 0.73 | SMN1; SMN2 (0.37) | CYP2D6SLC6A4SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9642579 | 0.72 | SMN1; SMN2 (0.54) | CYP2D6SLC6A2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12830571 | 0.71 | TSHR (0.59) | SMN1; SMN2ALDH1A1KDM4ETSHRHTR2A | |
| SCHEMBL398940 | 0.71 | HSD17B10 (0.42) | CYP2D6SLC6A2SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL14092176 | 0.70 | MAPT (0.38) | SLC6A4KCNH2SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949949-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2017-02-16 | — | — | US | disclosed |
| US-9371297-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | CYP2D6 2960/4885SLC6A2 3566/4885SLC6A4 2398/4885 |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | CYP2D6 2807/4885SLC6A2 3772/4885SLC6A4 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.